1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → N-Cyclopropyl-4-methoxy-2,6-dimethyl-N-[(4-{[4-(1-methylpiperidin-4-yl)piperazin-1-yl]carbonyl}-1,3-oxazol-2-yl)methyl]benzenesulfonamide

2-({Cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino}methyl)-1,3-oxazole-4-carboxylic acid (100 mg, 0.26 mmol) was dissolved in DCM (15 mL) and EDCI (70 mg, 0.36 mmol), HOBt (53 mg, 0.39 mmol) and DIPEA (0.057 mL, 0.33 mmol) were added. The resulting solution was stirred for 15 min prior to the addition of 1-(1-methylpiperidin-4-yl)piperazine (57 mg, 0.31 mmol) dissolved in DCM (2 mL) and stirred at ambient temperature for 12 h. The reaction was diluted with DCM (20 mL) and washed with water (10 mL), saturated aqueous NaHCO3 (10 mL), saturated brine (5 mL), dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by FCC with 0-2% MeOH in DCM to afford the title compound as pale yellow oil.

1. stirringstirred at ambient temperature for 12 h
2. washwashed with water (10 mL), saturated aqueous NaHCO3 (10 mL), saturated brine (5 mL)
3. dry with materialdried over Na2SO4
4. concentrationconcentrated in vacuo
5. customThe resulting residue was purified by FCC with 0-2% MeOH in DCM

ORD record

ord-948e46a6993342f38e67ceb1aa804caf

Source dataset

uspto-grants-2014_01

DOI

10.6084/m9.figshare.5104873.v1

Patent number

US08623859B2